| Serial Number | 98380457 |
| Word Mark | INVIVOKINES |
| Filing Date | Monday, January 29, 2024 |
| Status | 681 - PUBLICATION/ISSUE REVIEW COMPLETE |
| Status Date | Monday, August 26, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, October 1, 2024 |
| Pseudo Mark | IN VIVO KINES |
| Goods and Services | Biochemical proteins for scientific, pre-clinical, and clinical research; Biochemical proteins for use in translational in vivo research; Biochemical proteins for use in immunotherapeutic research; Biochemical proteins for use in medical research; Bioreagents for scientific, pre-clinical, and clinical research; Bioreagents for use in translational in vivo research; Bioreagents for use in immunotherapeutic research; Bioreagents for use in medical research |
| International Class | 001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry. |
| US Class Codes | 001, 005, 006, 010, 026, 046 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, January 29, 2024 |
| Primary Code | 001 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Adipogen Life Sciences, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | San Diego, CA 92121 |
| Event Date | Event Description |
| Monday, January 29, 2024 | NEW APPLICATION ENTERED |
| Tuesday, May 28, 2024 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Friday, August 23, 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, September 11, 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Friday, August 23, 2024 | ASSIGNED TO EXAMINER |